Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to NSCLC
Related studies linked through entity extraction aliases.
Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer
- Status
- COMPLETED
- Phase
- NA
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE3
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
- Status
- COMPLETED
- Phase
- N/A
A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711
- Status
- COMPLETED
- Phase
- PHASE1
A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711
- Status
- COMPLETED
- Phase
- PHASE1
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- Status
- RECRUITING
- Phase
- PHASE2
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
- Status
- TERMINATED
- Phase
- N/A
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
- Status
- TERMINATED
- Phase
- PHASE2
To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
- Status
- UNKNOWN
- Phase
- NA
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)
- Status
- UNKNOWN
- Phase
- PHASE4
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation
- Status
- COMPLETED
- Phase
- PHASE2